Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying
内部人士正在买入Duos Technologies和其他两只低于3美元的股票
The Dow Jones index closed higher by 0.2% on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周二收盘上涨0.2％。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将此视为他们整体投资或交易决策的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是细价股最近几笔值得注意的内幕交易。欲了解更多信息，请访问Benzinga的内幕交易平台。
Bespoke Extracts
定制提取物
- The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod bought a total of 2,000 shares at an average price of $0.13. To acquire these shares, it cost around $268.
- What's Happening: The company's stock lost around 48% over the past six months.
- What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.
- 交易：Bespoke Extracts, Inc.（场外交易代码：BSPK）首席执行官迈克尔·费恩索德共购买了2,000股股票，平均价格为0.13美元。收购这些股票的成本约为268美元。
- 发生了什么：该公司的股票在过去六个月中下跌了约48％。
- Bespoke Extracts的作用：Bespoke Extracts Inc专注于销售其专有系列的特殊配方、优质、大麻衍生的CBD产品。
Ocuphire Pharma
Ocuphire Pharma
- The Trade: Ocuphire Pharma, Inc. (NASDAQ:OCUP) CEO George Magrath acquired a total of 5,000 shares at an average price of $1.75. To acquire these shares, it cost around $8,773.
- What's Happening: On May 10, Ocuphire Pharma posted a wider-than-expected quarterly loss.
- What Ocuphire Pharma Does: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.
- 交易：Ocuphire Pharma, Inc.（纳斯达克股票代码：OCUP）首席执行官乔治·马格拉思共收购了5,000股股票，平均价格为1.75美元。收购这些股票的成本约为8,773美元。
- 发生了什么：5月10日，Ocuphire Pharma公布的季度亏损超出预期。
- Ocuphire Pharma做什么：Ocuphire Pharma Inc是一家临床阶段的眼科生物制药公司，专注于开发和商业化治疗屈光和视网膜眼病的疗法。
Duos Technologies
Duos 科技
- The Trade: Duos Technologies Group, Inc. (NASDAQ:DUOT) CEO Charles Parker Ferry acquired a total of 3,773 shares at an average price of $2.70. The insider spent around $10,187 to buy those shares.
- What's Happening: On May 13, Duos Technologies Group reported weaker than expected first-quarter sales.
- What Duos Technologies Does: Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs.
- 交易：Duos Technologies Group, Inc.（纳斯达克股票代码：DUOT）首席执行官查尔斯·帕克·费里共收购了3,773股股票，平均价格为2.70美元。知情人士花费了约10,187美元购买了这些股票。
- 发生了什么：5月13日，Duos Technologies集团报告称，第一季度销售额低于预期。
- Duos Technologies的业务：以其品牌名称duostech运营的Duostech集团公司设计、开发、部署和运营智能技术解决方案，为铁路、物流和多式联运业务提供支持，从而简化运营、提高安全性并降低成本。
Read More: Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
阅读更多：本月可能挽救您的投资组合的五大医疗保健股票